

Arnoud J Templeton

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2800708/arnoud-j-templeton-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86
papers

4,789
citations

29
h-index

69
g-index

89
ext. papers

5,827
ext. citations

6
avg, IF

5.38
L-index

#	Paper	IF	Citations
86	Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.. <i>European Urology Open Science</i> , 2022 , 40, 16-18	0.9	0
85	Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 1-9	7.3	1
84	Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6571-6571	2.2	
83	Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer. <i>PLoS ONE</i> , 2020 , 15, e0233768	3.7	1
82	Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1651-1654	2.2	25
81	Informative censoring - a neglected cause of bias in oncology trials. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 327-328	19.4	17
80	Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 7052-7052	2.2	
79	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2020 , 28, 107-114	2.8	3
78	Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. <i>Cancer Medicine</i> , 2020 , 9, 7888-7895	4.8	2
77	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019 , 24, 1188-1194	5.7	17
76	Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w) (ARX 06/12 (REDUSE)). <i>Journal of Clinical Oncology</i> , 2019 , 37, 133-133	2.2	5
75	Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2019 , 2, 448-455	6.7	2
74	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 486-492	9.7	43
73	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e277-e287	3.3	4
72	Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. <i>Cancer Treatment Reviews</i> , 2018 , 62, 1-8	14.4	41
71	Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer. <i>Future Science OA</i> , 2018 , 4, FSO253	2.7	5
70	Vitamin D levels in Swiss breast cancer survivors. <i>Swiss Medical Weekly</i> , 2018 , 148, w14576	3.1	3

69	Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. <i>Oncotarget</i> , 2018 , 9, 15061-15067	3.3	0
68	Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. <i>Radiation Oncology</i> , 2018 , 13, 216	4.2	21
67	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017 , 145, 584-594	4.9	58
66	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. <i>Molecular Diagnosis and Therapy</i> , 2017 , 21, 337-343	4.5	3
65	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. <i>Cancer Treatment Reviews</i> , 2017 , 56, 1-7	14.4	30
64	Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. <i>Experimental and Molecular Pathology</i> , 2017 , 102, 455-474	4.4	12
63	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research</i> , 2017 , 19, 2	8.3	277
62	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2299-2305	2.2	153
61	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017 , 60, 53-59	14.4	17
60	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2017 , 59, 46-53	14.4	2
59	Neutrophils in cancer: prognostic role and therapeutic strategies. <i>Molecular Cancer</i> , 2017 , 16, 137	42.1	169
58	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18336-e18336	2.2	
57	Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5022-5022	2.2	
56	A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16003-e16003 ²		
55	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , 2016 , 114, 207-12	8.7	38
54	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 1-8	4.4	8
53	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016 , 70, 358-64	10.2	112
52	Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2016 , 2, 744-50	13.4	12

51	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 399-406	4	25
50	Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. <i>European Urology</i> , 2016 , 69, 980-3	10.2	11
49	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2016 , 11, e0154789	3.7	23
48	In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. <i>Oncotarget</i> , 2016 , 7, 22865-72	3.3	17
47	Study of testosterone-guided androgen deprivation therapy in management of prostate cancer. <i>Prostate</i> , 2016 , 76, 235-42	4.2	1
46	Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. <i>International Journal of Cancer</i> , 2016 , 138, 671-8	7.5	47
45	Relevance of randomised controlled trials in oncology. <i>Lancet Oncology, The</i> , 2016 , 17, e560-e567	21.7	48
44	Under-reporting of harm in clinical trials. <i>Lancet Oncology, The</i> , 2016 , 17, e209-19	21.7	61
43	The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. <i>Cancer Medicine</i> , 2016 , 5, 2792-2799	4.8	56
42	Influence of censoring on conclusions of trials for women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2015 , 51, 721-4	7.5	11
41	Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. <i>European Urology</i> , 2015 , 68, 506-15	10.2	27
40	Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. <i>European Urology</i> , 2015 , 67, 740-9	10.2	129
39	Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2015 , 68, 839-43	3.9	4
38	Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. <i>Journal of Clinical Oncology</i> , 2015 , 33, 100-6	2.2	34
37	Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 23-8	3.6	20
36	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015 , 6, 39538-49	3.3	23
35	Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). <i>Breast</i> , 2014 , 23, 244-9	3.6	15
34	Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 147-52	4.8	62

33	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1048-55	14.4	27
32	Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt319	9.7	216
31	Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1204-12	4	401
30	Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 317-24	3.3	53
29	Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). <i>European Urology</i> , 2014 , 66, 468-74	10.2	76
28	Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 235-44	4.4	55
27	Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju124	9.7	1552
26	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e95219	3.7	119
25	Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3197	2.2	2
24	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , 2014 , 120, 3346-52	6.4	98
23	Use and misuse of waterfall plots. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	17
22	Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. <i>Prostate</i> , 2014 , 74, 1462-4	4.2	3
21	Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. <i>Oncology Research and Treatment</i> , 2014 , 37, 772-6	2.8	19
20	Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5077-5077	2.2	1
19	Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6550-6550	2.2	1
18	Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 159-159	2.2	6
17	Neutrophil to lymphocyte ratio and response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 477-477	2.2	2
16	Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 61-61	2.2	1

15	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 70-70	2.2	3
14	Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e88238	3.7	40
13	Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 547-547	2.2	
12	Effect of multifocality and multicentricity on outcome in early breast cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 546-546	2.2	2
11	Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5047-5047	2.2	
10	Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 43-43	2.2	
9	Benefit and harms of new anti-cancer drugs. <i>Current Oncology Reports</i> , 2013 , 15, 270-5	6.3	23
8	Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). <i>European Urology</i> , 2013 , 64, 150-8	10.2	101
7	Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4130-4130	2.2	1
6	Management of small HER2 overexpressing tumours. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 289-93	4.4	11
5	Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. <i>European Urology</i> , 2011 , 60, 1235-43	10.2	41
4	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3342-7	11.5	153
3	Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1760-70	9.7	57
2	Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. <i>Urologia Internationalis</i> , 2009 , 83, 122-4	1.9	7
1	Concordant colon tumors in monozygotic twins previously treated for prostate cancer. <i>Familial Cancer</i> , 2009 , 8, 167-71	3	4